Expert Financial Analysis and Reporting

Key Points: I am projecting that total sales will increase from $19.6 million in 2018 to $31.0 million in 2019 and $83.9 million in 2024. This is a fourfold increase in sales over the 2018 to 2024 period. Even though these numbers appear to be aggressive, I have tried to go out of my way […]

Quick Comment on 4Q, 2018 Sales and Earnings Report Cryoport reported a spectacular 4Q, 2018 quarter last night. Biopharma revenues which are 84% of total revenues increased 94% to $4.9 million which compared to my estimate of $4.3 million. Total revenues increased 72% to $5.7 million as compared to my estimate of $5.2 million. The […]

Investment Thesis The proposed acquisition of Celgene by Bristol-Myers Squibb was generally panned by Wall Street investors and analysts as BMY stock dropped 14% on the news. The investment community is deeply concerned with the patent situation with Revlimid which accounts for over 60% of CELG revenues. There will be full blown generic entries in […]

Cryoport raises $25 million warchest for acquisiitons

Key Points Cryoport continued to show explosive growth in the third quarter as sales increased 76% to $5.3 million led by a 91% increase in biopharma (83% of total) sales. I am projecting a 60% increase in sales in 2019 to $30.7 million again led by a 69% increase in biopharma. (Detailed sales and a […]

Key Investment Points of this Report Regenerative medicines promises to be a (the) major technology driving the biopharma industry in coming decades. The CAR-T products are the first commercially significant products stemming from this technology, but they are just the tip of a very large iceberg. Novartis, Gilead and Celgene have gained first mover status […]

Investment Perspective On May 16, 2018, I published a report entitled Updated Sales and Earnings Model. The purpose of that report was to build a detailed sales model for the Company that for the first time incorporated Cryoport revenues arising from the sale of commercial products-the CAR-T drugs Kymriah and Yescarta. You may want to […]

Purpose of this Report With the commercial launches of the CAR-T products Kymriah and Yescarta, I am expecting a significant upward inflection in sales for Cryoport. The primary objective of this report is to formulate an improved sales and earnings model in order to show this. First quarter results from Cryoport, Novartis and Gilead have […]

Investment Conclusions Along with most investors interested in Cryoport, I am expecting and awaiting a sharp upward inflection in sales as the CAR-T products gain traction in the market. Novartis’ Kymriah and Gilead’s Yescarta are both in early stages of their launches- Kymriah for pediatric r/r ALL and Yescarta for r/r DLBCL. In its conference […]

Cryoport reported 4Q results pretty much in line with my expectations. In my last report on November 6, 2017, I projected 4Q biopharma revenues (obviously the critical business segment) of $2.673 million and the Company reported $2.516 million. I guess you might call this a 157,000 shortfall (6% below projection), but well within the error […]